Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 2,798 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Light Clear all
Completed Phase 4 Interventional Results available

8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension

NCT01570686
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
43
States / cities
Los Angeles, California • Riverside, California • Santa Monica, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 23, 2026, 5:29 AM EDT
Withdrawn Not applicable Interventional

Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy

NCT01542983
View directory record Official record
Conditions
Stage, Breast Cancer
Interventions
Brief behavioral treatment for insomnia and bright light, treatment as usual
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 85 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Combination of Magnesium and Lidocaine for the Pretreatment of Pain That is Caused by the Injection of Propofol

NCT01342510
View directory record Official record
Conditions
General Anesthesia, Intravenous Anesthesia
Interventions
Magnesium Sulfate, Lidocaine, Control, Lidocaine/Magnesium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 23, 2026, 5:29 AM EDT
Withdrawn Not applicable Interventional

Development of a Neonatal Jaundice Treatment Accelerator by Redirection of Unused Light During Phototherapy

NCT04021927
View directory record Official record
Conditions
Jaundice, Jaundice, Neonatal
Interventions
Ring Phototherapy
Device
Lead sponsor
University of Minnesota
Other
Eligibility
Up to 7 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Not applicable Interventional

Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.

NCT00812188
View directory record Official record
Conditions
Symmetric Limited Morphea
Interventions
Medium Dose UVA-1, High Dose UVA-1
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 23, 2026, 5:29 AM EDT
Terminated Phase 2 Interventional

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

NCT02728388
View directory record Official record
Conditions
NEUROFIBROMATOSIS 1
Interventions
aminolevulinic acid
Drug
Lead sponsor
Donald Basel
Other
Eligibility
14 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

NCT04109924
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colon Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Recurrent Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Colorectal Carcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride
Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Tampa, Florida • New Brunswick, New Jersey • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects

NCT04531527
View directory record Official record
Conditions
Dermatitis, Phototoxic
Interventions
Butenafine HCl 1% (BAY1896425)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 23, 2026, 5:29 AM EDT
Completed No phase listed Observational

Improving the Assessment of Hypersomnolence

NCT02884505
View directory record Official record
Conditions
Disorders of Excessive Somnolence
Interventions
Pupillometry, Psychomotor Vigilance Task, Auditory Evoked Potential, Hypersomnia Severity Index
Device · Behavioral · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain Vascular and Neurocognitive Health

NCT06497413
View directory record Official record
Conditions
Cognitive Decline, Cognitive Dysfunction, Alzheimer Disease, Vascular Disease, Peripheral
Interventions
Transcranial Photobiomodulation, Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus) with no light administered
Device
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 23, 2026, 5:29 AM EDT
Withdrawn Not applicable Interventional

Treatment of Infected Dialysis Catheters With Fiber Optic Ultraviolet Light

NCT02899780
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
Ultraviolet light emitting optical fiber
Device
Lead sponsor
Ultraviolet Interventions
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

NCT02292758
View directory record Official record
Conditions
Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Bevacizumab, Cetuximab, Irinotecan, Laboratory Biomarker Analysis, Placebo
Biological · Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Scottsdale, Arizona • Boise, Idaho • Sioux City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 23, 2026, 5:29 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms

NCT07686198
View directory record Official record
Conditions
Photodamaged Skin
Interventions
Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy, Left Arm treated with vehicle serum and Intense Pulsed Light Therapy
Drug
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 5:29 AM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers

NCT05255016
View directory record Official record
Conditions
Keratitis, Corneal Ulcer
Interventions
PXL Platinum 330 system + Riboflavin 0.25% TE Solution, Sham CXL + Artificial Tears
Combination Product · Other
Lead sponsor
Peschke GmbH
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 23, 2026, 5:29 AM EDT
Terminated Not applicable Interventional

Perception-Action Approach vs. Passive Stretching for Infants With Congenital Muscular Torticollis

NCT02824848
View directory record Official record
Conditions
Congenital Muscular Torticollis
Interventions
Passive Stretching, Perception-Action Approach
Behavioral
Lead sponsor
Rosalind Franklin University of Medicine and Science
Other
Eligibility
Up to 9 Months
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Visual Activity Evoked by Infrared in Humans After Dark Adaptation

NCT02909985
View directory record Official record
Conditions
Age Related Macular Degeneration, Retinitis Pigmentosa, Congenital Stationary Night Blindness, Colorblindness
Interventions
Tungsten halogen light with narrow bandpass filters
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Not applicable Interventional Results available

Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture

NCT02579343
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Auricular Acupuncture, Sham Auricular Acupuncture + Lexapro
Device · Drug
Lead sponsor
Florida Gulf Coast University
Other
Eligibility
18 Years to 24 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 23, 2026, 5:29 AM EDT
Enrolling by invitation Not applicable Interventional

Spectral Lighting and Metabolism

NCT06094504
View directory record Official record
Conditions
Intestinal Failure
Interventions
Spectral Lighting
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 1 Year
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 5:29 AM EDT
Not yet recruiting Phase 2 Interventional

Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis

NCT07524634
View directory record Official record
Conditions
Amyloid Light-chain Amyloidosis
Interventions
BCMA bispecific
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Rochester, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 23, 2026, 5:29 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Repurposing Lithium for Parkinson's Disease: a RCT

NCT06339034
View directory record Official record
Conditions
Parkinson Disease
Interventions
Lithium, Placebo
Dietary Supplement · Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VelaShape III Device in Comparison to Cryolipolysis for Circumferential Reduction

NCT02143960
View directory record Official record
Conditions
Abdominal Fat
Interventions
VelaShape III, CoolSculpt
Device
Lead sponsor
Syneron Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Not applicable Interventional Results available

Personalized Integrated Chronotherapy for Perinatal Depression

NCT04364646
View directory record Official record
Conditions
Depression, Postpartum Depression, Prenatal Disorder, Circadian Dysregulation, Pregnancy Related, Sleep Disturbance
Interventions
Personalized Integrated Chronotherapy
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Glen Oaks, New York • Chapel Hill, North Carolina • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 23, 2026, 5:29 AM EDT
Not listed Phase 2Phase 3 Interventional

Collagen Cross-Linking for Keratoconus/Ectasia With and Without Intacs

NCT01081561
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Yaron S. Rabinowitz M.D.
Other
Eligibility
21 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea

NCT02268474
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Interventions
532nm KTP Laser vs 595nm Pulse Dye Laser
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
20 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 23, 2026, 5:29 AM EDT